JAK Inhibition as a New Treatment Strategy for Patients with COVID-19
Top Cited Papers
- 11 May 2020
- journal article
- review article
- Published by S. Karger AG in International Archives of Allergy and Immunology
- Vol. 181 (6), 467-475
- https://doi.org/10.1159/000508247
Abstract
After the advent of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the outbreak of coronavirus disease 2019 (COVID-19) commenced across the world. Understanding the Immunopathogenesis of COVID-19 is essential for interrupting viral infectivity and preventing aberrant immune responses before a vaccine can be developed. In this review, we provide the latest insights into the roles of angiotensin-converting enzyme II (ACE2) and Ang II receptor-1 (AT1-R) in this disease. Novel therapeutic strategies, including recombinant ACE2, ACE inhibitors, AT1-R blockers, and Ang 1–7 peptides, may prevent or reduce viruses-induced pulmonary, cardiac, and renal injuries. However, more studies are needed to clarify the efficacy of these therapeutics. Furthermore, considering the common role of the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway in AT1-R expressed on peripheral tissues and cytokine receptors on the surface of immune cells, potential targeting of this pathway using JAK inhibitors (JAKinibs) is suggested as a promising approach in patients with COVID-19 who are admitted to hospitals. In addition to antiviral therapy, potential ACE2- and AT1-R-inhibiting strategies, and other supportive care, we suggest other potential JAKinibs and novel anti-inflammatory combination therapies that affect the JAK-STAT pathway in patients with COVID-19. Since the combination of MTX and baricitinib leads to outstanding clinical outcomes, the addition of baricitinib to MTX might be a potential strategy.Keywords
This publication has 43 references indexed in Scilit:
- Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexateAnnals Of The Rheumatic Diseases, 2014
- Tofacitinib versus Methotrexate in Rheumatoid ArthritisThe New England Journal of Medicine, 2014
- Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical applicationBiomarker Research, 2013
- Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in MyelofibrosisJournal of Clinical Oncology, 2011
- Human immunopathogenesis of severe acute respiratory syndrome (SARS)Virus Research, 2008
- Angiotensin II induces IL-6 expression and the Jak-STAT3 pathway in aortic adventitia of LDL receptor-deficient miceAtherosclerosis, 2007
- Clathrin-Dependent Entry of Severe Acute Respiratory Syndrome Coronavirus into Target Cells Expressing ACE2 with the Cytoplasmic Tail DeletedJournal of Virology, 2007
- A Human Homolog of Angiotensin-converting EnzymeJournal of Biological Chemistry, 2000
- Methotrexate specifically modulates cytokine production by T cells and macrophages in murine collagen-induced arthritis (CIA): a mechanism for methotrexate-mediated immunosuppressionClinical and Experimental Immunology, 1999
- Accumulation of Hyaluronan (Hyaluronic Acid) in the Lung in Adult Respiratory Distress SyndromeAmerican Review of Respiratory Disease, 1989